Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
| Autor: | Aran F. Labrijn, Thorbald van Hall, Kristel Kemper, Patrick J. Engelberts, Jim Middelburg, Janine Schuurman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Bispecific antibody CD3-bispecific antibody medicine.medical_treatment CD3 Review on-target off-tumor toxicity lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Clinical investigation Medicine tumor-associated antigens immuno-oncology antibody therapy Tumor microenvironment biology business.industry T-cell engager T-cell co-stimulation Cancer Immunotherapy solid tumors medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030104 developmental biology Oncology 030220 oncology & carcinogenesis biology.protein Cancer research Antibody business Antibody therapy |
| Zdroj: | Cancers, Vol 13, Iss 287, p 287 (2021) Cancers Cancers, 13(2). MDPI |
| ISSN: | 2072-6694 |
| Popis: | Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is currently successfully used in the clinic to treat tumors in the blood and is under investigation for tumors in our organs. The treatment of these solid tumors faces more pronounced hurdles, which affect the safety and efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of this field and identify intrinsic hurdles for solid cancers. Furthermore, we describe potential solutions and combinatorial approaches to overcome these challenges in order to generate safer and more effective therapies. Abstract Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|